SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are…
| Price | $3.17 |
|---|---|
| Market cap | $227.01M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NASDAQ |
| 52-week range | 2.83-9.45 |
| Dividend (TTM) | $1.20 per share |
| Beta | 0.89 |
Explore SIGA's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.